Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA HEALTHWISE HOLDINGS LIMITED
中國智能健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 348)

INSIDE INFORMATION
PROFIT WARNING

This announcement is made by China Healthwise Holdings Limited (the "**Company**" and together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provision (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on a preliminary assessment of the Group's unaudited consolidated management accounts for the six months ended 30 June 2026 ("**PE2026**"), the Group expects to record a loss attributable to owners of the Company within the range of approximately HK$28.0 million to HK$30.0 million, as compared to a profit attributable to the owners of the Company of approximately HK$1.4 million for the six months ended 30 June 2025 ("**PE2025**").

The shift from profit to loss attributable to owners of the Company was principally due to (1) an increase in loss on disposal of financial instruments from approximately HK$0.2 million for PE2025 to approximately HK$11.7 million for PE2026; (2) an unrealised fair value loss on financial assets at fair value through profit or loss of approximately HK$4.7 million for PE2026, as compared to an unrealised fair value gain of approximately HK$12.4 million for PE2025; and (3) an impairment loss recognised under the expected credit loss model in respect of the Group's loan receivables of approximately HK$0.1 million for PE2026, as compared to a reversal of impairment loss of approximately HK$3.1 million for PE2025.

The Board wishes to emphasise that the information contained in this announcement is based on the preliminary assessment of the latest information currently available to the Board, which have not been audited or reviewed by the Company's independent auditor. As at the date of this announcement, the Company's interim results for PE2026 have not been finalised and are still subject to possible adjustments and allowances, and may be significantly different from the information disclosed herein. The interim results of the Company for PE2026 are scheduled to be approved and announced by the Board on 27 August 2026.

Shareholders and potential investors are advised to exercise caution in dealing in the shares of the Company.

By Order of the Board
China Healthwise Holdings Limited
Lei Hong Wai
Chairman and Executive Director

Hong Kong, 25 August 2026

As at the date of this announcement, the executive Directors are Mr. Lei Hong Wai (Chairman), Mr. Cheung Kwok Wai Elton (Vice Chairman), Mr. Leung Alex, Ms. Lo Ming Wan and Mr. Yuan Huixia; and the independent non-executive Directors are Mr. Fung Wai Ching, Mr. Lai Hok Lim and Mr. Tsang Chin Pang.